At its meeting on 12 September 2022 the Transparency Council adopted position No. 86/2022 on the evaluation of drug: Ponvory (ponesimod) under the drug programme “Treatment of multiple sclerosis (ICD-10 G35)”.
Publication in Public Information Bulletin (BIP)